WHO: Integrated drug resistance action framework for HIV, hepatitis B and C and STIs, 2026–2030

The WHO integrated drug resistance action framework for HIV, hepatitis B and C, and sexually transmitted infections (2026–2030) outlines a unified global approach to address drug resistance, a growing threat that risks undermining decades of progress toward ending AIDS and the epidemics of hepatitis B, hepatitis C, and sexually transmitted infections (STIs). Developed through broad and inclusive consultation, and aligned with the WHO Global Health Sector Strategies and the Sustainable Development Goals, the framework promotes a people-centred approach and antimicrobial stewardship across 5 key domains: prevention and response, surveillance, research and innovation, laboratory capacity, and governance.

Grounded in equity and in a public health approach, the framework emphasises country ownership and sustainability and encourages innovation while strengthening strategic coordination and partnerships among governments, communities, researchers, and global stakeholders. By integrating disease-specific and cross-cutting actions, it aims to reinforce health systems, expand access to high-quality and stigma-free services, and preserve the effectiveness of lifesaving medicines.

Its goal is clear: to prevent the emergence and spread of drug resistance so that efforts to end AIDS and the epidemics of hepatitis B, hepatitis C, and sexually transmitted infections as public health threats remain achievable by 2030.

Access the WHO integrated drug resistance action framework for HIV, hepatitis B and C, and sexually transmitted infections (2026–2030) here.